Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Hikvision Foresees Overseas Customer Losses Amid U.S. Blacklisting
As Investors Circle Milk Tea-Makers, Experts Warn of Coming Bubble
China Online Retail Sales Growth Slows but Stays in Double-Digits
LATEST
Chinese Fintech Firm 51 Credit Card Raided by Police
China Net Execs Tout ‘Industrial Web’ at World Internet Conference
China Online Retail Sales Growth Slows but Stays in Double-Digits
As Investors Circle Milk Tea-Makers, Experts Warn of Coming Bubble
Hikvision Foresees Overseas Customer Losses Amid U.S. Blacklisting
Tencent-Backed E-Book Platform Partners With Disney for ‘Star Wars’ Project
iQiyi Looks to AI to Force-Feed Ads to Viewers
Popular Walking App Accused of Financial Fraud
WeWork Putting the Brakes on China Push: Report
‘No New Progress’ on Zotye Joint-Venture With Ford
Qutoutiao’s Online Literature Unit Gets $100 Million Windfall
NBA’s China Crisis Has Already Caused ‘Substantial’ Losses, Commissioner Says
Northern China Aims to Curb Toxic Air Pollution by 4% This Winter
China’s Economic Growth Dips to New Nearly Three-Decade Low
Tesla’s China Plant Is Hooked Up to State Grid Power Supply
Didi Pushes Further Into Latin America With Eye on Costa Rica
Homeowners Demand Refunds After Developer Cuts Prices
Controversial WeChat Public Account Operator Eyes High-Tech Board IPO
Burgeoning Online Marketplace in Crisis After Luring New Shoppers With Merchants’ Money
Huawei Posts Strong Revenue Growth Despite U.S. Export Ban
China’s Rising Vaccine Star Struggles to Reassure Investors After Halting Production

By Zhao Runhua, Wang Luyao and Liu Denghui / Apr 09, 2019 03:42 PM / Business & Tech

Photo: VCG

Photo: VCG

A rising star in China’s biotech industry is now raising concerns about the country’s ability to produce its own vaccines.

Chongqing Zhifei Biological has halted the production of its own meningitis vaccine AC-Hib, the company announced last week – a move that may keep investors at bay.

The company’s previous license to produce the vaccine expired April 1, and it has yet to receive a new one, despite having applied for renewal in November, according to the company’s official statement.

Regulations stipulate that a company needs to apply for a license once every five years in order to produce a vaccine, and Zhifei’s last approval for AC-Hib came in 2014. It is not clear if its license’s renewal this time around has been postponed or rejected.

Zhifei still sells HPV vaccines developed by global giant MSD, with which it shares revenues for China sales, but the AC-Hib has been a major revenue channel for the company.

Industry watchers say Zhifei’s case signals the increasingly tight supervision of vaccine production after scandals caused nationwide concern. Last year, Changsheng Bio-Technology caused outrage after it was found to have produced and sold roughly 500,000 substandard vaccines for babies.

Zhifei booked a total 2018 revenue of 5.2 billion yuan ($744 million), up 289.4% year-on-year. And the company’s net profit climbed 235.8% to 1.5 billion yuan for the same period.

But even strong overall performance may not reassure investors – an 8 billion yuan market value of the company's stock in Shenzhen Growth Enterprise Market evaporated in just one day after company’s statement. Since then, the company’s stock has dropped over 10%.

Related: 4 Things to Know About China’s Vaccine Scandal

 


Share this article
Open WeChat and scan the QR code